GVHD is a clinical problem that has no predictive markers and is a source of high morbidity and mortality for the recipient. Our Lab has used microarrays and QPCR to find a novel gene panel in peripheral blood that can predict the onset of chronic GVHD. These studies are currently being cross-validated in RCT in bone marrow transplants with our collaborators at the Fred Hutchinson Institute and the University of Miami.